Growth metabolism
| Product name | IGFBP-1Insulin like Growth Factor Binding Protein-1 | |||||||||
| Cat-Nr. | E01 | |||||||||
| Range | 0.1 - 128 ng/ml (after dilution 1:16) | |||||||||
| Sensitivity | 0.02 ng/ml | |||||||||
| Incubation time | 2 hours RT | |||||||||
| Sample volume | 20 µl (after dilution 1:16 for serum and plasma) | |||||||||
| Sample type | Serum, plasma (EDTA and Heparin), urine and other human body fluids, cell culture supernatants. Results in citrate plasma are about 15% reduced. | |||||||||
| Sample preparation | Samples have to be chilled as soon as possible after collection. Long-term storage should be carried out at –20°C or below. Maximum 3 freeze/thaw cycles. | |||||||||
| Reference values | Serum of healthy adults
| |||||||||
| Species | Human | |||||||||
| Tests | 96 Tests | |||||||||
| Method | ELISA | |||||||||
| Intended use | The Insulin-like Growth Factors I and –II are free in body fluids and tissues but are bound to specific binding proteins. Until today seven different binding proteins (IGFBP-1 to -7) can be differentiated, additionally several IGFBP-related proteins have also been detected. Bioavailability of IGF is regulated by these IGFBPs as well as their proteolytic fragments can also exert IGF-independent effects, like influencing cell migration or proliferation. IGFBP-1 (Placental Protein 12) consists of 234 aminoacids and has a molecular weight of approximately 25 kDa. The coding DNA region is located on chromosome 7. IGFBP-1 is mainly synthesized by foetal and adult liver tissue and decidual endometrium. Intensity of expression varies enduring menstruation with a maximal expression in the late secretory phase. Further IGFBP-1 expression seems to be regulated by Insulin concentration, with Insulin inhibiting the expression. Insulin regulation results in diurnal fluctuations of up to factor 10. In pregnancy IGFBP-1 maternal serum concentration increases significantly with maximal values in the second trimester or 22.-23. week of gestation (75,8 ng/ml) and decreases slowly until term. IGFBP-1 concentration are not only increased in maternal but also in foetal serum and with extremely high concentrations in amnion fluid. Here concentration can reach more than the 1000-fold of serum values. Short term IGFBP-1 serum concentration is strongly influenced by nutrition level and therewith by insulin. Decreasing IGFBP-1 levels can be found enduring fasting or in diabetes; IGFBP-1 levels increase in case of intensive exercises. Thoroughly investigated was the diagnostic value in insulin resistance and pre-term rupture of the membrane and specially in the second field a significant diagnostic value could be demonstrated.-Energy metabolism Based on the influence of Insulin on IGFBP-1 serum concentrations IGFBP-1 is said to be a possible marker for insulin resistance. Because measurement of IGFBP-1 is much easier facilitated than Glucose-uptake rate this would simplify diagnosis of insulin resistance. In a small study Maddux et al were able to demonstrate with 23 non-diabetic patients, that IGFBP-1 serum concentration correlated very well with Glucose-uptake rate, even better than the HOMA index does. -Pregnancy In pregnancy a significant difference in IGFBP-1 serum concentration of healthy pregnant and diabetic and pre-eclamptic women was found (102,8 vs. 203,71 oder 281,09 ng/ml respectively). Also the evaluation of IGFBP-1 as marker for membrane rupture showed a high specificity (97%) and sensitivity (75%) of IGFBP-1 in vaginal/cervical secrets. In this study IGFBP-1 concentrations of >100 ng/ml were set as threshold for detection of amnion fluid and therewith diagnosis of membrane rupture. A positive predictive value of 97% clearly shows that IGFBP-1 is a suitable marker for premature membrane rupture. | |||||||||
| Product informations | Kit Instructions (PDF 825,4 kB) Cross-reaction all species (PDF 74,6 kB) |
Back to overview
tecomedical总部位于瑞士的TECOmedical Group在德国，法国和比荷卢三国设有子公司，是医学和兽医诊断，生物安全和环境测试领域体外专业测试系统的领先提供商。此外，我们与意见领袖合作开发或评估新的测试系统，或为制药，CRO和研究组织提供服务。
本网站将在规定时间内给予删除等相关处理。
